The promise of decentralised models and diversity in clinical trials

Biopharma perspective

ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently or likely to address diversity and inclusion in clinical trials into the future.

Executive report

Read our summary report for insight into how organisations responded rapidly to the developments in 2020 and how this is paving the way for continuous improvements into the future.

Contact us

For more information on decentralised trials, diversity in clinical trials or to speak with one of our experts, please contact us.

Enquiry form

Practical considerations in transitioning to hybrid or decentralised clinical trials

Everyone is talking about decentralised clinical trials. But how can we leverage what we learnt during 2020 and move forward in a more systematic way to deploy this approach with maximum efficiency and optimum results?

Read the whitepaper